Of all the new science coming in through ASH 2019, one of the most important abstracts is this one from Roche (RHHBY).
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
If current excitement surrounding the ASH is all about CAR-T, then this abstract stands out because it is looking at patients who have already gone through a CAR-T therapy and have either relapsed or were resistant to it. So, mosunetuzumab